Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I Study of HL-003 in Healthy Subjects
NCT06867393Phase 1Recruiting
- Sponsor
- Shanghai KeChow Pharmaceuticals
- Start
- Feb 2025
- Primary completion
- Aug 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of HL-003 in xerostomia and acute kidney injury (AKI) (4 arms), sponsored by Shanghai KeChow Pharmaceuticals. Primary endpoints: Incidence and severity of treatment-related adverse events that were intolerable up to 3 days and Incidence of TEAEs up to 3 days. Started Feb 2025; status: recruiting.
02
Drugs
HL-003
03
Conditions
xerostomiaacute kidney injury (AKI)
Beyond the preview
Go deeper on NCT06867393.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06867393.